Establishment of a dynamic osteosarcoma biobank: Ruijin experience.

Outcomes for patients with metastatic and recurrent osteosarcoma remain poor and a better understanding of the biology of this malignancy is critical to the development of prognostic biomarkers and novel therapies. The purpose of this study was to establish a biobank of osteosarcoma which has the potential of monitoring tumors dynamically with exosomes, to facilitate clinical and basic scientific research. The osteosarcoma biological specimen and clinical data of osteosarcoma were collected in Ruijin Hospital in two stages. In the first stage (2015-2017), the collection of tissue specimens and blood samples were performed at diagnostic biopsy, definitive surgery, recurrence and lung metastasis, according to the Children's Oncology Group protocol. In the second stage (2017-2019), the tissue specimens were collected the same as before, but the blood samples were collected at the beginning of each MAP-I (methotrexate, cisplatin, doxorubicin, ifosfamide) chemotherapy cycle, and every 6 months after the last chemotherapy up to 3 years, according to our modified protocol, to dynamically monitor the status of possible alteration of gene expression profiling in the osteosarcoma. A total of 268 patients with osteosarcoma were enrolled in this study, 161 were men and 107 were women, with the mean age of 24.51 ± 15.58 years. Local recurrence occurred in 29 patients and lung metastasis in 51. The numbers of tissue and blood specimens reached 360 and 1023, respectively. 11 specimens were from recurrent osteosarcoma and 25 were from lung metastasis. The corresponding clinical and demographic data were collected in our electronic database. The osteosarcoma biobank built with our modified protocol mentioned above has the potential of monitoring tumors dynamically with exosomes and could provide specimens to the researches improving the biological understanding and outcome of this disease.